ES2961390T3 - Montelukast para el tratamiento de la osteoartritis erosiva de la mano - Google Patents

Montelukast para el tratamiento de la osteoartritis erosiva de la mano Download PDF

Info

Publication number
ES2961390T3
ES2961390T3 ES19805716T ES19805716T ES2961390T3 ES 2961390 T3 ES2961390 T3 ES 2961390T3 ES 19805716 T ES19805716 T ES 19805716T ES 19805716 T ES19805716 T ES 19805716T ES 2961390 T3 ES2961390 T3 ES 2961390T3
Authority
ES
Spain
Prior art keywords
montelukast
pharmaceutically acceptable
acceptable salt
day
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19805716T
Other languages
English (en)
Spanish (es)
Inventor
Faure Jordi Monfort
Milano Josep Verges
Alonso Fernando Garcia
Massana Jordi Ramentol
Garcia José Angel Sanchez
Menendez Nuria Sanz
De La Torre Marta Vicario
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmalider SA
Original Assignee
Farmalider SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider SA filed Critical Farmalider SA
Application granted granted Critical
Publication of ES2961390T3 publication Critical patent/ES2961390T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES19805716T 2018-11-26 2019-11-25 Montelukast para el tratamiento de la osteoartritis erosiva de la mano Active ES2961390T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382851 2018-11-26
PCT/EP2019/082425 WO2020109230A1 (en) 2018-11-26 2019-11-25 Montelukast for the treatment of erosive hand osteoarthritis

Publications (1)

Publication Number Publication Date
ES2961390T3 true ES2961390T3 (es) 2024-03-11

Family

ID=64665075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19805716T Active ES2961390T3 (es) 2018-11-26 2019-11-25 Montelukast para el tratamiento de la osteoartritis erosiva de la mano

Country Status (22)

Country Link
US (1) US12539296B2 (enExample)
EP (1) EP3886857B1 (enExample)
JP (1) JP7399502B2 (enExample)
CN (1) CN113347975B (enExample)
AU (1) AU2019386235B2 (enExample)
BR (1) BR112021009980A2 (enExample)
CA (1) CA3120920C (enExample)
DK (1) DK3886857T3 (enExample)
ES (1) ES2961390T3 (enExample)
FI (1) FI3886857T3 (enExample)
HR (1) HRP20231283T1 (enExample)
HU (1) HUE063579T2 (enExample)
MA (1) MA54276B1 (enExample)
MD (1) MD3886857T2 (enExample)
MX (1) MX2021006209A (enExample)
MY (1) MY203365A (enExample)
PL (1) PL3886857T3 (enExample)
PT (1) PT3886857T (enExample)
RS (1) RS64668B1 (enExample)
SI (1) SI3886857T1 (enExample)
TW (1) TWI850283B (enExample)
WO (1) WO2020109230A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4228641A1 (en) * 2020-10-13 2023-08-23 Diomed Developments Limited Gel formulations comprising montelukast
GB2599912B (en) * 2020-10-13 2023-04-19 Diomed Dev Ltd New formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201020085D0 (en) * 2010-11-26 2011-01-12 Xaragen Pharma Ltd Methods and reagents for the treatment of arthritic disorders
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis

Also Published As

Publication number Publication date
MX2021006209A (es) 2021-08-11
SI3886857T1 (sl) 2023-12-29
PT3886857T (pt) 2023-10-25
HUE063579T2 (hu) 2024-01-28
RS64668B1 (sr) 2023-11-30
AU2019386235B2 (en) 2024-11-21
JP2022508236A (ja) 2022-01-19
TWI850283B (zh) 2024-08-01
US20220047570A1 (en) 2022-02-17
FI3886857T3 (fi) 2023-10-20
EP3886857A1 (en) 2021-10-06
CA3120920A1 (en) 2020-06-04
JP7399502B2 (ja) 2023-12-18
MD3886857T2 (ro) 2023-12-31
PL3886857T3 (pl) 2024-01-15
CN113347975B (zh) 2024-08-30
AU2019386235A1 (en) 2021-07-01
CA3120920C (en) 2024-01-02
DK3886857T3 (da) 2023-10-09
WO2020109230A1 (en) 2020-06-04
US12539296B2 (en) 2026-02-03
EP3886857B1 (en) 2023-07-26
BR112021009980A2 (pt) 2021-08-17
HRP20231283T1 (hr) 2024-02-02
MY203365A (en) 2024-06-26
MA54276B1 (fr) 2023-11-30
TW202038954A (zh) 2020-11-01
CN113347975A (zh) 2021-09-03
MA54276A (fr) 2021-10-06

Similar Documents

Publication Publication Date Title
ES2245511T3 (es) Lociones de vitamina d3 activa en forma de emulsion.
ES2366646T3 (es) Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
TWI351959B (en) Combination of brimonidine and timolol for topical
ES2627405T3 (es) Composiciones que comprenden brimonidina para el tratamiento del eritema
ES2741146T3 (es) Formulaciones farmacéuticas de nitrio y sus usos
ES2991885T3 (es) Fenitoína tópica para su uso en el tratamiento del dolor neuropático periférico
ES2961390T3 (es) Montelukast para el tratamiento de la osteoartritis erosiva de la mano
KR20080105864A (ko) 리마프로스트를 함유하는 경추증의 치료 및/또는 증상 진전억제제
US20230302008A1 (en) Methods of administering intravenous meloxicam in a bolus dose
RU2101014C1 (ru) Анальгезирующее, противовоспалительное, жаропонижающее лекарственное средство и способ его получения
JP2022505572A (ja) 術前および他の薬物との組み合わせでのメロキシカムの静脈内投与方法
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
EP3352734A1 (en) Treatment of alopecia areata
WO2013115737A2 (en) New pharmaceutical compositions of flurbiprofen and glucosamin
HK40054679A (en) Montelukast for the treatment of erosive hand osteoarthritis
HK40054679B (en) Montelukast for the treatment of erosive hand osteoarthritis
KR20230018481A (ko) 질병의 치료를 위한 2-(다이에틸아미노)에틸 2-(4-아이소부틸페닐)프로피오네이트의 국소 투여
CN106714803A (zh) 眼用混悬液制剂
ES2717299T3 (es) Una combinación de unidades de dosificación para su uso en el tratamiento del parto prematuro
JP2008156232A (ja) リマプロストを含有してなる頚椎症の治療および/または症状進展抑制剤
NZ540415A (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
KR20060123329A (ko) 월경 곤란증의 예방 및/또는 치료제
UA122476C2 (uk) М'яка лікарська форма для місцевого лікування поверхневих інфантильних гемангіом
BR112012030704B1 (pt) Composição farmacêutica de cocristais e processo para sua produção
PT85135B (pt) Processo para a preparacao de misturas de diflunisal e trometamina